The Drug Evaluation and Classification (DEC) program is used by police agencies to identify drivers impaired because of drug use and to determine the class(es) of drug causing the impairment. The primary goal of this study was to determine the validity of the DEC evaluation in predicting whether research volunteers were administered alprazolam, d-amphetamine, codeine, or marijuana. A secondary goal was to determine the accuracy of Drug Recognition Examiners (DREs) in detecting if subjects were dosed with these drugs. Community volunteers (n = 48) were administered alprazolam (0, 1, 2 rag), d-amphetamine (0, 12.5, 25 rag), codeine (0, 60, 120 rag), or marijuana (0, 3.58% THC) in a double-blind, randomized, between-subject design. A single drug dose or placebo was administered at each experimental session, and blood samples were obtained before and after dosing. With the exception of marijuana, plasma drug concentration was at or near maximum during the DEC evaluation. The ability of the DEC evaluation to predict the intake of alprazolam, d-amphetamine, codeine, or marijuana was optimal when using 2-7 variables from the evaluation. DREs' decisions of impairment were consistent with the administration of any active drug in 76% of cases, and their drug class decisions were consistent with toxicology in 32% of cases, according to standards of the International Association of Chiefs of Police. These findings suggest that the DEC evaluation can be used to predict accurately acute administration of alprazolam, d-amphetamine, codeine, and marijuana and that predictions of drug use may be improved by focusing on a subset of variables.
Introduction
The Drug Evaluation and Classification (DEC) program was developed by the Los Angeles Police Department during the 1970s because of a need to identify and document ifa driver was impaired due to recent drug ingestion. Studies investigating the *Author to whom correspondence should be addressed: Stephen J. Heishman, Ph.D., Clinical Pharmacology Branch, NIDA Addiction Research Center, 5500 Nathan Shock Drive, Baltimore, MD 21224. E-mail: Sheish@intra.nida.nih.gov.
prevalence rate of drugs other than ethanol in fatally injured drivers have reported varied results, ranging from 6% to 37% (1) (2) (3) (4) (5) . Among individuals stopped for reckless driving who were judged to be clinically intoxicated, urine drug testing indicated 85% were positive for cannabinoids, cocaine metabolites, or both (6) . These relatively high prevalence rates reinforce the general assumption that psychoactive drugs are capable of impairing driving (7, 8) . Drug prevalence rates do not imply impaired driving; however, because of the reliability with which certain drugs degrade psychomotor and cognitive performance in the laboratory (9) , it is highly likely that many drug-related vehicular accidents and DUI/DWI arrests involve impaired behaviors critical for safe driving. Currently, few standardized methods exist for identifying and measuring performance impairment caused by psychoactive drugs. The DEC program consists of a standardized evaluation conducted by a trained police officer (Drug Recognition Examiner, DRE) and the toxicological analysis of a biological specimen. The evaluation involves a breath-alcohol test; examination of the suspect's appearance, behavior, and eyes; field sobriety tests (FST); vital signs; and questioning of the suspect (10) . From the evaluation, the DRE concludes the following: 1. if the suspect is behaviorally impaired such that he or she is unable to operate a motor vehicle safely, 2. if the impairment is drug related, and 3. the drug class(es) likely causing the impairment. The DEC program uses seven drug classes: central nervous system (CNS) depressants, CNS stimulants, hallucinogens, phencyclidine, narcotic analgesics (opioids), inhalants, and cannabis. The toxicological analysis either corroborates the DRE's drug class opinion or it does not.
The DEC program is currently operational in 40 states and the District of Columbia. A study of the impact of the DEC program on traffic enforcement and adjudication in five states reported that DRE cases typically result in a conviction on an impaireddriving charge (11) . Several field studies have indicated that DREs' opinions were confirmed by toxicological analysis in 74-92% of cases when DREs concluded suspects were impaired (11) (12) (13) (14) (15) . In a laboratory study (16) , DREs evaluated research volunteers who were dosed with d-amphetamine, diazepam, secobarbital, and marijuana. Results indicated that DREs correctly identified the drug class in 92% of cases when subjects were judged impaired and correct identifications were dose dependent. These studies attest to the validity of the DEC program as a measurement of drug-induced behavioral impairment.
Recently, we began to evaluate the validity of the individual variables of the DEC evaluation as predictors of drug intake under controlled laboratory conditions. In an initial study (17) , we administered one placebo and two active doses of ethanol, cocaine, and marijuana to research subjects before being evaluated by DREs. Results showed that 17-28 variables of the DEC evaluation predicted the presence or absence of each of the three drugs with a high degree of sensitivity and specificity and low rates of false-positive and false-negative errors. These findings indicated that the DEC evaluation can be used to predict accurately acute administration of ethanol, cocaine, or marijuana.
In this second study, we examined the validity of the DEC evaluation variables in predicting whether research volunteers had been administered alprazolam, d-amphetamine, codeine, or marijuana. A secondary goal was to determine the accuracy of the DREs' evaluations in detecting if subjects had been dosed with these drugs. The ultimate goal of these studies is to refine the DEC evaluation by determining which variables are best predictors of drug intake across a range of drug classes, thereby aiding DREs in their decision process.
Methods

Research subjects
Participants were 48 community volunteers (42 men, 6 women) who ranged in age from 24 to 39 years (mean = 31.8, SD = 4.1). Before the study, subjects were given thorough psychiatric and physical examinations and were interviewed about past and current drug use. They entered one of four drug experiments depending on their drug history. Subjects (n = 12) in the alprazolam study reported a history of CNS depressant (ethanol, benzodiazepines) use ranging from 9 to 27 years (mean = 16.4, SD = 6.0) and average current use of 6.3 times in the 2 weeks before admission. Subjects (n --12) in the d-amphetamine study reported a history of CNS stimulant (cocaine) use ranging from 4 to 21 years (mean = 11.5, SD = 5.5) and average current use of 9.3 times in the 2 weeks before admission. Subjects (n = 12) in the codeine study reported a history of heroin use ranging from 2 to 17 years (mean = 7.5, SD = 4.5) and average current use of 4.3 times in the previous 2 weeks. Subjects (n = 12) recruited into the marijuana study reported a history of marijuana use ranging from 5 to 25 years (mean = 14.8, SD = 6.3) and average current use of 5.4 times in the 2 weeks before admission.
Subjects provided written informed consent according to guidelines for the protection of human subjects of the Department of Health and Human Services and were paid for their participation.
Drug Recognition Examiners
Thirty DREs (28 men, 2 women) representing eight states participated in the study. All DREs were certified according to stan-
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Journal of Analytical Toxicology, Vol, 22, October 1998 dards of the International Association of Chiefs of Police (IACP), the agency responsible for DRE certification (18) . DREs had no contact with research subjects before or after the DEC evaluation. DREs were told that the study might involve ethanol and five classes of drugs (CNS depressants, CNS stimulants, phencyclidine, narcotics, and cannabis), that all combinations of ethanol and those drugs could be administered, and that subjects would receive no active drug on some sessions. DREs were not permitted to interrogate subjects, except for two questions about physical defects and vision problems.
Drug administration
Alprazolam (Upjohn, Kalamazoo, MI) was administered in doses of 0, 1, and 2 rag; d-amphetamine sulfate (SmithKline Beecham, Philadelphia, PA) in doses of 0, 12.5, and 25 rag; and codeine phosphate (Roxane, Columbus, OH) in doses of 0, 60, and 120 mg. Doses of d-amphetamine and codeine were calculated on the basis of the salt. Alprazolam, d-amphetamine, and codeine were administered orally in opaque capsules. Lactose was used as capsule filler for lower doses and for placebo capsules.
Marijuana cigarettes were supplied by the National Institute on Drug Abuse (Rockville, MD) and contained either 0 (placebo) or 3.58% (active) Ag-tetrahydrocannabinol (THC) by weight. Cigarettes were cut in half, and subjects smoked two halfcigarettes at will. The second half-cigarette was begun 7 rain from the start of smoking. Total smoking time was about 12 min. Placebo, low, and high marijuana doses consisted of two placebo half-cigarettes, one placebo and one active half-cigarette, and two active half-cigarettes, respectively.
Drugs were administered under double blind conditions according to a randomized, Latin-square design. For all sessions across the four experiments, capsules (active drug or placebo) were administered 140 rain and 80 rain before the DEC evaluation, and cigarette (active or placebo marijuana) smoking ended 20 rain before the evaluation. For each session, only one drug was active, the others placebo, d-Amphetamine was administered at 140 min; alprazolam and codeine were administered 80 rain before the evaluation. This dosing schedule ensured that plasma drug concentrations and/or drug effect would be at or near maximum at time 6f the DEC evaluation (19) .
Experimental procedures
Subjects resided on the closed research unit of the Addiction Research Center. They were informed that the purpose of the study was to investigate the effects of commonly abused drugs on behavior, mood, and performance. Subjects were told that they would be observed by law enforcement officials who would attempt to determine if they had received active drug(s). They were instructed not to discuss with the DREs what drug(s) they thought they received. Each subject participated in one of four concurrent experiments; each experiment lasted 4 weeks and tested one of the four study drugs (see Drug administration section). Each experiment consisted of seven sessions, which were separated by at least 72 h. The first session was a safety test in which subjects received the high drug dose to identify potential untoward reactions. No DEC evaluation was conducted on the first session. In the remaining six sessions, subjects were administered placebo and two active drug doses twice in random order. Before each session, subjects ate a light breakfast, and an indwelling catheter was inserted in a nondominant forearm vein. A battery of measures (vital signs, pupillometry, blood, subjective ratings, and performance) was assessed predrug and at specific postdrug times. The DEC evaluation began 20 rain after marijuana smoking ended and lasted about 25 rain. Testing occurred between 11:00 and 12:00 h for all subjects.
DEC evaluation
A complete description of the DEC evaluation used in this study has been described (17) . Briefly, the DEC evaluation consisted of a breath test for alcohol; assessment of eye tracking, nystagmus, and convergence; performance of four FST: Romberg Balance (RB), Walk and Turn (WT), One Leg Stand (OLS), and Finger to Nose (FN); measurement of vital signs; examination of the pupils in ambient room light, nearly total darkness, indirect light, and direct light; and assessment of muscle tone, attitude, coordination, speech, breath odor, and facial appearance. DREs did not question subjects about recent drug use, nor did they interrogate subjects to solicit admissions about drug use. If a conclusion of impairment was reached, DREs recorded their opinion of the drug class(es) causing the impairment.
Collection and analysis of blood samples
Blood samples were collected on ice in 7-mL Monoject | tubes containing sodium fluoride and potassium oxalate. Samples were centrifuged, and the plasma was transferred to silanized borosilicate tubes with sealed teflon-lined caps. Samples were stored at-20~ and shipped frozen on dry ice to the Center for Human Toxicology (Salt Lake City, tiT) where the analyses were performed.
Alprazolam. Analysis of alprazolam and a-hydroxyalprazolam
(a-OH-ALP) was performed by liquid-liquid extraction and negative ion chemical ionization mass spectrometry using 1-mL aliquots of controls, calibrators, and subject plasma (20) . Drugfree plasma was fortified with drug reference solutions to produce calibration curves from 0.25 to 50 ng/mL. Controls were analyzed at 1 and 20 ng/mL. Plasma samples suspected of containing concentrations exceeding 50 ng/mL were diluted with drug-free plasma, and a 1-mL volume of the dilution was extracted. Deuterium-labeled alprazolam and a-OH-ALP were used as internal standards. Samples were extracted with toluene/methylene chloride (7:3) and derivatized with N,Obis(trimethylsilyl)trifluoroacetaminde containing 1% trimethylchlorosilane (Pierce Chemical, Rockford, IL) before gas chromatography-mass spectrometry (GC-MS) analysis. The analyses were performed using a Finnigan MAT 4500 MS equipped with a 9610 GC, INCOS software, and a CTC A200S autosampler (Finnigan MAT, San Jose, CA). The MS was operated in the negative ion detection mode with methane as the reagent gas. Chromatographic separation was achieved on a 15-m • 0.25-ram Restek-200 | fused-silica capillary column (Restek, Bellefonte, PA) using hydrogen as the carrier gas. The limit of quantitation (LOQ) for both analytes was 0.25 ng/mL. Intraassay percent coefficients of variation (%CVs) for alprazolam and a-OH-ALP were < 16.1, _< 6.9, and 5 4.6 at 0.5, 5.0, and 50 ng/mL, respectively. Interassay %CVs for alprazolam and a-OH-ALP were _< 16.2, _< 14.7, and < 9.5 at 1.0, 5.0, and 50 ng/mL, respectively (20) .
d-Amphetamine. Analysis of d-amphetamine was performed
by liquid-liquid extraction and positive ion chemical ionization MS using 1-mL aliquots of controls, calibrators, and subject plasma. Drug-free plasma was fortified with drug reference solutions to produce calibration curves from 5 to 200 ng/mL. Controls were analyzed at 50 ng/mL. Plasma samples suspected of containing concentrations exceeding 200 ng/mL were diluted with drug-free plasma, and a 1-mL volume of the dilution was extracted. Deuterium-labeled d-amphetamine was used as the internal standard. Samples were extracted with n-butylchloride/chlorofrom (4:1) and derivatized with trifluoroacetic anhydride before GC-MS analysis (21, 22) . The anatyses were performed using the described MS instrumentation. The MS was operated in the positive ion detection mode with a combination of methane and ammonia as the reagent gas. Chromatographic separation was achieved on a 30orn x 0.25-mrn DB-1 | fused-silica capillary column (J&W Scientific, Folsom, CA) using helium as the carrier gas. The LOQ for amphetamine was 5.0 ng/mL. Intra-and interassay %CVs for amphetamine at 50 ng/mL were less than 15.
Codeine. Analysis of codeine and its metabolite morphine was performed by solid-phase extraction (SPE) and positive ion chemical ionization MS using 1-mL aliquots of controls, calibrators, and subject plasma. Drug-free plasma was fortified with drug-reference solutions to produce calibration curves from 5 to 500 ng/mL. Controls were analyzed at 250 ng/mL. Plasma samples suspected of containing concentrations exceeding 500 ng/mL were diluted with drug-free plasma, and a 1-mL volume of the dilution was extracted. Deuterium-labeled codeine and morphine were used as internal standards. Samples were derivatized with trifluoroacetic anhydride before GC-MS analysis (21, 22) . Analyses were performed using the described MS equipment. The MS was operated in the positive ion detection mode with a combination of methane and ammonia as the reagent gas. Chromatographic separation was achieved on a 15-m x 0.25-ram DB-1 fused silica capillary column (J&W Scientific) with helium as the carrier gas. Interassay %CVs for codeine and morphine were 17.3 and 13.3, respectively (23).
Marijuana. Analysis of THC and 11-nor-9-carboxy-Ag-tetrahydrocannabinol (THCCOOH) was performed by SPE and negative ion chemical ionization MS (24) using 1-mL aliquots of controls, calibrators, and subject plasma. Calibrators were prepared by fortifying drug-free plasma with THC and THCCOOH through the concentration range of 0.5 to 100 ng/mL. Controls were analyzed at 5 ng/mL for THC and 20 ng/mL for THCCOOH. Samples suspected of containing concentrations exceeding the calibration curve were diluted with drug free plasma and a 1-mL volume of the dilution was extracted. Deuterium-labeled THC and THCCOOH were used as internal standards. The eluant from SPE was divided into two equal fractions. One fraction was derivatized with trifluoroacetic anhydride for the quantitation of THC. The second fraction, which contained THCCOOH, was derivatized with BF3/methanol and subsequently with trifluoroacetic anhydride. The GC-MS analysis used the instrumentation described; the MS was operated in the negative ion detection mode with methane as the reagent gas. Chromatographic separation was achieved on a 15-m x 0.32-rnm DB-] fused-silica capillary column (J&W Scientific) using hydrogen as the carrier gas. The LOQs for THC and THCCOOH were 0.5 ng/mL and 1.0 ng/mL, respectively. Interassay %CVs were 8.6 and 7.0 at 1.6 ng/mL and 9.5 and 1.6 at 25 ng/mL for THC and THCCOOH, respectively (17) .
Data analysis
The DEC examination yielded 100 variables, which were transformed into 76 variables to approximate the DREs' evaluation process. The transformed data from 6 sessions for 48 subjects yielded a data set containing 288 cases. There were 8 sessions for which DREs were unavailable, resulting in a total of 280 valid cases.
The transformed data were subjected to four forward stepwise discfiminant analyses (25) that reduced the transformed data to subsets of 2-7 variables making up the best predictors of the presence or absence of each of the four study drugs. These subsets of best-predictor variables for each drug were then subjected to separate discriminant function analyses that predicted and classified whether subjects were dosed or not dosed with each drug. The resultant data were interpreted using the following definitions:
9 True positive (TP). Subjects dosed with active drug and identified as dosed. 9 True negative (TN). Subjects not dosed with active drug and identified as not dosed. 9 False positive (FP). Subjects not dosed with active drug and identified as dosed. 9 False negative (FN). Subjects dosed with active drug and identified as not dosed. These parameters were then used to calculate the following measures of predictive accuracy of the DEC evaluation (26,27): 9 Sensitivity. TP x 100/(TP + FN) = the incidence of TP results in the sample when the evaluation was conducted with dosed subjects (i.e., the probability that a dosed subject was identi fled as dosed). 9 Specificity. TN x 100/(TN + FP) = the incidence of TN results in the sample when the evaluation was conducted with nondosed subjects (i.e., the probability that a non-dosed subject was identified as not dosed). 9 False-positive rate. FP x 100/(FP + TN) = the percentage of subjects in the sample identified as dosed by the evaluation when they were not dosed. 9 False-negative rate. FN x 100/(FN + TP) = the percentage of subjects in the sample identified as not dosed when they were dosed. 9 Efficiency. (TP + TN)/(TP + TN + FP + FN) = the percentage of all subjects in the sample identified accurately, whether dosed or not dosed.
Results
Plasma data
During each experimental session, eight blood samples were obtained at predrug baseline and up to 12 h postdrug. A complete report of the pharmacokinetic data will be published elsewhere. We report here plasma drug concentrations from the postdrug samples obtained 20 rain before and immediately after the DEC evaluation. These blood samples corresponded to the following postdrug times: alprazolam, 60 and 105 rain; d-amphetamine, 120 and 145 rain; codeine, 60 and 105 rain; and marijuana, 2 and 45 rain.
Mean plus or minus standard error (SE) plasma concentrations of alprazolam at 60 min postdrug were 12.9 • 1.7 and 25.8 • 2.9 ng/mL and at 105 min postdrug were 15.5 • 1.5 and 31.3 • 2.0 ng/mL for the 1 and 2 mg doses, respectively. Plasma concentrations of both doses plateaued from 105 to 180 min and declined gradually to 9-18 ng/mL at 11 h postdrug. Plasma concentrations of co-OH-ALP were not detected for either dose in most subjects. Codeine produced mean plus or minus SE peak plasma concentrations at 60 rain postdrug of 120.8 _ 14.8 and 265.8 • 28.8 ng/mL for the 60 and 120 mg doses, respectively. At 105 rain postdrug, plasma codeine concentrations were 114.1 _+ 9.1 and 229.6 • 17.8 ng/mL for the low and high doses, respectively. Plasma concentrations of both doses declined to less than 15 ng/mL at 11 h postdrug. Morphine concentrations were not detected for either dose in most subjects. d-amphetamine (Canonical R = .68, p < .001). The three variables in descending order of predictive weight were as follows: 1. increased sum of three pulse recordings, 2. increased sum of systolic and diastolic blood pressure, and 3. decreased errors on OLS test. The discfiminant function comprising these variables predicted the presence or absence of d-amphetamine with moderate to high accuracy (Table II) . As with alprazolam, the model's predictions had greater specificity than sensitivity and a lower false-positive rate compared with false-negative rate. Efficiency Codeine. The stepwise discfiminant analysis of the 76 transformed variables resulted in a subset of two variables that were the best predictors of the presence or absence of codeine (Canonical R = .35, p < .001). The two variables in descending order of predictive weight were 1. decreased sum of pupillary diameter and 2. decreased rebound dilation of the pupils. The discfiminant function comprising these variables predicted the presence or absence of codeine with relatively low accuracy (Table III) . Sensitivity was low, and the false-negative rate was high. In contrast, specificity was high, and the false-positive rate was relatively low. Efficiency of the model was moderate.
Marijuana. The stepwise discfiminant analysis of the 76 transformed variables resulted in a subset of seven variables that were the best predictors of the presence or absence of marijuana (Canonical R = .65, p < .001). The seven variables in descending order of predictive weight were as follows: 1. increased sum of three pulse recordings, 2. abnormal eyes, 3. increased sum of the pupillary diameter, 4. bloodshot eyes, 5. increased errors on FN test, 6. slowed pupillary reaction to light, and 7. increased errors in OLS count. Table IV shows that the discriminant function comprising these variables predicted the presence or absence of marijuana with moderate to high accuracy. The model predicted with greater accuracy the absence of marijuana than its pres-ence. As with the other drugs, the false-positive rate was lower than the false-negative rate. Figure 1 shows DRE decisions for each drug as a function of dose. For alprazolam, decisions of no impairment decreased with increasing dose. An equal number of predictions of impairment due to CNS depressants were made for both active alprazolam doses; however, at the high dose, more impairment decisions were based on other drugs than on depressants. DREs concluded that the majority of subjects dosed with d-amphetamine were not impaired. For both active doses of d-amphetamine, DREs concluded that subjects were dosed with other drugs more than with d-amphetamine. Similarly, DREs concluded that most subjects dosed with codeine were not impaired; however, there was a dose-related increase in predictions of impairment due to narcotic analgesics (opioids). Decisions regarding marijuana did not show orderly dose-related trends. At the low marijuana dose, DREs concluded that more subjects were not impaired and fewer were impaired due to marijuana compared with subjects receiving placebo. At the high marijuana dose, this decision pattern was reversed.
DRE predidions
To obtain and maintain IACP certification, DREs' drug-class predictions must be "consistent" with toxicological analysis. Under IACP standards (18) , the following rules apply: 1. if the DRE concludes a subject is impaired by only one drug class, toxicology must confirm some drug in that class; 2. if the DRE names two drug classes, toxicology must confirm at least one of them; and 3. if the DRE names three or more drug classes, toxicology must confirm at least two. DREs are not expected to identify all drugs taken by a subject, only those that account for the observed impairment. IACP standards accept an analysis of blood, urine, saliva, or any body tissue or fluid that produces an identification of a drug or metabolite to confirm the DRE's opinion.
Tables V-VIII present drug dose administered, DRE decisions of drug class(es) causing impairment, and consistency of the decision according to IACP standards for each of the 288 experimental sessions. Table IX ).
Discussion
The primary goal of this study was to determine the validity of the DEC evaluation variables in predicting whether research volunteers had been administered alprazolam, d-amphetamine, codeine, marijuana, or placebo. Using discriminant function analysis, it was found that 2-7 variables of the DEC evaluation predicted the presence or absence of alprazolam, d-amphetamine, and marijuana with a moderate sensitivity, high specificity, low false-positive rates, and relatively high false-negative rates. For codeine, sensitivity was low, and false-negative rates were extremely high. We used criterion-related validation procedures to determine the validity of the DEC evaluation. Criterion-related validity refers to accuracy of a test in predicting performance by comparing actual performance with an independent criterion, which the test is designed to predict (28) . Because the DEC evaluation is used to predict drug intake, drug dose was chosen as the criterion measure in this study. Mathematical models were developed that identified which subsets of variables best predicted if subjects were dosed with placebo or each active drug. The subsets consisted of seven variables for alprazolam, three variables for d-amphetamine, two variables for codeine, and seven variables for marijuana. These subsets of best predictor variables were smaller in size compared to our previous study, in which we reported subsets of 17-28 variables (17) . Additionally, Heishman et al. (17) reported that the mathematical models predicted the presence or absence of drug with greater accuracy (high sensitivity and specificity and low false-positive and false-negative rates) than that observed in the present study. The less overt behavioral effects of d-amphetamine and codeine, which resulted in few DRE impairment decisions (see Figure 1) , and the lower marijuana doses used in this study were probable reasons for these discrepancies between the two studies. Nonetheless, the predictive efficiency of the model for each drug in this study ranged from 73 to 90, indicating a moderate to high degree of predictive validity.
The validity of the DEC evaluation was extended further by the fact that the subsets of predictor variables included some of the known effects of each drug. The impaired motor abilities observed in this study after alprazolam administration (WT errors and abnormal speech) are consistent with its known deleterious effects on motor coordination and balance (29, 30) . Alprazolam and other benzodiazepines have been shown to produce ocular disturbances (31, 32) , but lack of convergence does not seem to have been described previously. Increased blood pressure and pulse are indicative of d-amphetamine's effects on the cardiovascular system (33) , and the improvement in performance on the OLS test is consistent with reports of amphetamines enhancing human performance (34) . The pupillary constriction observed with codeine is one of the classic signs of recent opioid use (35, 36) . With the excpetion of errors in the OLS count, all of the predictor variables for marijuana in this study were among the predictor variables identified in our previous study (17) . The best predictor of marijuana in both studies was increased pulse, which is the most reliable physiological sign of recent marijuana use (17, 37) . Marijuana decreases pupillary constriction velocity to a light flash (36) and causes nystagmus and transient visual disturbances (35) . There are contradictory reports of marijuana's effect on pupillary diameter (35) ; this study observed increased pupillary diameter, whereas Pickworth et al. (36) reported a decrease. The marijuana-induced impairment in motor coordination and balance (FN and OLS) observed in this study is consistent with previous research (17, 38) .
The secondary goal of this study was to determine the accuracy of the DREs' decisions in detecting whether an individual had been dosed with alprazolam, d-amphetamine, codeine, marijuana, or placebo. When DREs concluded subjects were impaired, their drug-class decisions were consistent with the administration of any active drug in 76% of cases, but consistent with toxicology under IACP standards in only 32% of cases. Thus, it would appear that DREs are able to detect drug-induced impairment in general, but have difficulty discriminating between various drugs. In our previous study (17) , non-ethanol drug class decisions were consistent with toxicology in 44% of cases. Nearly one-third of those non-ethanol decisions were consistent because of various drug metabolites identified in predose urine specimens. Although it is recognized that a positive urine drug test does not indicate behavioral impairment (39, 40) and probably did not significantly influence the DRE's drug-class decision (17) , the present study was conducted as a residential study on a closed research unit to avoid this potential confound.
The data from this and the previous study (17) clearly indicate that the variables of the DEC evaluation alone did not permit DREs to predict impairment and drug class with the accuracy observed in field studies (11) (12) (13) (14) (15) . There were several differences between the controlled laboratory conditions of these studies and typical field conditions that might account for this discrepancy. In the field, there is preliminary evidence (e.g., impaired driving, drugs or drug paraphernalia in possession, odor of marijuana) that is suggestive of drug use, and DREs know this before conducting the DEC evaluation. In this study, the odor of marijuana may have been misleading because subjects in the alprazolam, d-amphetamine, and codeine experiments smoked placebo marijuana cigarettes. In the field, DREs interview suspects after the DEC evaluation and may receive admissions of drug use; no such interviewing was permitted in this study. With the exception of alprazolam, which produced clear intoxication at the 2-mg dose, the other drugs produced only moderate behavioral effects. It is possible that impaired drivers encountered by DREs have used greater drug doses or used drugs for a longer period of time than subjects in this study and thus may exhibit clearer clinical and behavioral signs of impairment. Finally, in this study, DREs were told that several drug classes and drug combinations might be administered, but only alprazolam, d-amphetamine, codeine, and marijuana were administered alone.
Whereas the DREs were limited in their ability to identify drug-impaired behavior for the reasons discussed, the mathematical models, which were designed to identify the best predictor variables of the DEC evaluation for each drug, were strongly biased toward making correct predictions. A computer is far superior to humans in its ability to integrate data from 76 variables and generate an accurate prediction. Thus, it is not fair to compare the predictive accuracy of the DREs and the mathematical models. The primary intent of this study was an examination of the validity of the DEC evaluation and a determination of which variables of the evaluation best predicted if an individual had been dosed with various drugs. To this end, DREs' decisions on drug class might be improved if attention were focused on the best predictors identified by the mathematical models.
Conclusion
The DEC evaluation is a valid test to identify recent drug use.
Results of this and our previous study (17) indicate that a certain subset of variables of the DEC evaluation can be used to predict accurately acute administration of alprazolam, d-amphetamine, marijuana, ethanol, cocaine, and to a lesser extent, codeine. In this study, predictive validity was optimal when predictions were made using 2-7 variables from the DEC evaluation. These findings suggest that predictions of impairment and drug use may be improved if DREs focus on a subset of variables associated with each drug class rather than the entire DEC evaluation.
